BACKGROUND: Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine malignancy with a propensity for regional and distant spread. Because of the relative infrequency of this disease, the patterns of metastasis in MCC are understudied. METHODS: Patients with American Joint Committee on Cancer (8th edition) stage I-IV MCC treated at our institution were identified (1/1/2008-2/28/2018). The first site of metastasis was classified as regional [regional lymph node (LN) basin, in-transit] or distant. Distant metastasis-free (DMFS) and MCC-specific (MSS) survival were estimated. RESULTS: Of 133 patients, 64 (48%) had stage I, 13 (10%) stage II, 48 (36%) stage III, and 8 (6%) stage IV disease at presentation. The median follow-up time in patients who remained alive was 36 (interquartile range 20-66) months. Regional or distant metastases developed in 78 (59%) patients. The first site was regional in 87%, including 73% with isolated LN involvement, and distant in 13%. Thirty-seven (28%) patients eventually developed distant disease, which most commonly involved the abdominal viscera (51%) and distant LNs (46%) first. The lung (0%) and brain (3%) were rarely the first distant sites. Stage III MCC at presentation was significantly associated with worse DMFS (hazard ratio 4.87, P = 0.001) and stage IV disease with worse MSS (hazard ratio 6.30, P = 0.002). CONCLUSIONS: Regional LN metastasis is the most common first metastatic event in MCC, confirming the importance of nodal evaluation. Distant disease spread appears to have a predilection for certain sites. Understanding these patterns could help to guide surveillance strategies.
BACKGROUND: Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine malignancy with a propensity for regional and distant spread. Because of the relative infrequency of this disease, the patterns of metastasis in MCC are understudied. METHODS: Patients with American Joint Committee on Cancer (8th edition) stage I-IV MCC treated at our institution were identified (1/1/2008-2/28/2018). The first site of metastasis was classified as regional [regional lymph node (LN) basin, in-transit] or distant. Distant metastasis-free (DMFS) and MCC-specific (MSS) survival were estimated. RESULTS: Of 133 patients, 64 (48%) had stage I, 13 (10%) stage II, 48 (36%) stage III, and 8 (6%) stage IV disease at presentation. The median follow-up time in patients who remained alive was 36 (interquartile range 20-66) months. Regional or distant metastases developed in 78 (59%) patients. The first site was regional in 87%, including 73% with isolated LN involvement, and distant in 13%. Thirty-seven (28%) patients eventually developed distant disease, which most commonly involved the abdominal viscera (51%) and distant LNs (46%) first. The lung (0%) and brain (3%) were rarely the first distant sites. Stage III MCC at presentation was significantly associated with worse DMFS (hazard ratio 4.87, P = 0.001) and stage IV disease with worse MSS (hazard ratio 6.30, P = 0.002). CONCLUSIONS: Regional LN metastasis is the most common first metastatic event in MCC, confirming the importance of nodal evaluation. Distant disease spread appears to have a predilection for certain sites. Understanding these patterns could help to guide surveillance strategies.
Authors: Yun Song; Feredun S Azari; Daniel Aryeh Metzger; Douglas L Fraker; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2019-09-04 Impact factor: 5.344
Authors: Daniel G Coit; John A Thompson; Mark R Albertini; Christopher Barker; William E Carson; Carlo Contreras; Gregory A Daniels; Dominick DiMaio; Ryan C Fields; Martin D Fleming; Morganna Freeman; Anjela Galan; Brian Gastman; Valerie Guild; Douglas Johnson; Richard W Joseph; Julie R Lange; Sameer Nath; Anthony J Olszanski; Patrick Ott; Aparna Priyanath Gupta; Merrick I Ross; April K Salama; Joseph Skitzki; Jeffrey Sosman; Susan M Swetter; Kenneth K Tanabe; Evan Wuthrick; Nicole R McMillian; Anita M Engh Journal: J Natl Compr Canc Netw Date: 2019-04-01 Impact factor: 11.908
Authors: Jennifer L Schwartz; Kent A Griffith; Lori Lowe; Sandra L Wong; Scott A McLean; Douglas R Fullen; Christopher D Lao; James A Hayman; Carol R Bradford; Riley S Rees; Timothy M Johnson; Christopher K Bichakjian Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Ryan C Fields; Klaus J Busam; Joanne F Chou; Katherine S Panageas; Melissa P Pulitzer; Dennis H Kraus; Mary S Brady; Daniel G Coit Journal: Ann Surg Oncol Date: 2011-03-24 Impact factor: 5.344
Authors: John R Sims; Travis E Grotz; Barbara A Pockaj; Richard W Joseph; Robert L Foote; Clark C Otley; Amy L Weaver; James W Jakub; Daniel L Price Journal: Surg Oncol Date: 2017-10-26 Impact factor: 3.279
Authors: Tina I Tarantola; Laura A Vallow; Michele Y Halyard; Roger H Weenig; Karen E Warschaw; Travis E Grotz; James W Jakub; Randall K Roenigk; Jerry D Brewer; Amy L Weaver; Clark C Otley Journal: J Am Acad Dermatol Date: 2012-11-27 Impact factor: 11.527
Authors: Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem Journal: Nat Rev Dis Primers Date: 2017-10-26 Impact factor: 52.329
Authors: Francesca Spada; Paolo Bossi; Corrado Caracò; Vanna Chiarion Sileni; Angelo Paolo Dei Tos; Nicola Fazio; Giovanni Grignani; Michele Maio; Pietro Quaglino; Paola Queirolo; Paolo Antonio Ascierto Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469